On June 27, Mr. Nakamura, China Client Director of Dentsu Creative (Japan); Mr. Watanabe, General Manager of the Shenzhen Branch of Kokuyo (Japan Kokuyo Office) Co., LTD

; Zhang Fan from the Sales Department of Smart IC Co., Ltd.; Wang Jiannan, General Manager of Shenzhen Xinyang Investment Management Co., Ltd.， Chen Lili, Assistant to the General Manager of the aforementioned company; Yang Jun, Industry General Manager of Shenzhen Yawei Information Technology Group Co., Ltd.; Cheng Bing, Operations Manager of China-Canada Enterprise Innovation Centre; and Chen Qi, General Manager of henzhen Idea Touch Information Consulting Co., Ltd. visited Shenzhen Cell Valley Biomedical Co., Ltd. for inspection and exchange. Shenzhen Cell Valley's Chairman Professor Shi Yuanyuan, Chief Scientist Professor Wang Jianxun, Deputy General Manager Tang Xiaomeng, General Office Director Luan Zhishi, Assistant to the Chairman Wei Zheng, Sales Department Head Yang Borui, Sales Department Supervisor Yan Chengkun, and Marketing Department Supervisor Gulnara Halim warmly received them. Both parties held discussions on planned cooperation directions between China and Japan.

First, General Office Director Luan Zhishi led the Chinese and Japanese entrepreneurs on a tour of the company's Smart Exhibition Hall, providing a preliminary introduction to the company's vision, founder team, corporate development history, CAR-T development history, and service platform construction. Subsequently, a symposium was held.

During the symposium, Chairman Shi Yuanyuan first extended a warm welcome to the Chinese and Japanese entrepreneurs. Subsequently, General Office Director Luan Zhishi provided a detailed introduction in Japanese on the current status and development trends of cell therapy in China and Japan, Shenzhen Cell Valley's core products and services, technological advantages, comprehensive strength, and development strategy. Both parties then engaged in in-depth discussions and exchanges. Chairman Shi Yuanyuan stated that in terms of research and development planning for innovative technologies, China and Japan each have their own strengths. For example, Japan is a world leader in stem cell technologies (such as iPSC: induced pluripotent stem cells) and has achieved remarkable results in the field of anti-aging, while China has made breakthrough developments in cell therapy technologies such as CAR-T and CAR-NK. In the future, it is expected that pharmaceutical companies in China and Japan will strengthen linkages, accelerate the implementation of innovative products and cutting-edge therapies, and benefit more patients. At the same time, through the establishment of resource platforms, both sides hope to fully integrate the cutting-edge technologies in the cell therapy field from China and Japan, achieve complementary advantages in policies, talent, capital, and technology, and engage in in-depth cooperation in the cell and gene therapy field. By joining forces with high-quality resources from the Chinese and Japanese pharmaceutical industries, both parties can actively carry out cooperation, provide patients with high-quality Chinese and Japanese medical products and services, and achieve win-win outcomes.

The successful holding of this Sino-Japanese entrepreneur exchange event will effectively promote the advancement of cooperation between Shenzhen Cell Valley and Japanese enterprises in the cell and gene therapy industry. Shenzhen Cell Valley will fully leverage its technological and platform advantages in industrial-scale viral vector production, join forces with renowned Japanese companies, promote the entry of cell and gene therapy products into the Japanese market, and foster high-quality development in this field.

Dentsu Group (TYO: 4324), established in 1901, is the world's largest advertising and communications company, ranking among the Fortune Global 500. Its turnover has ranked first globally among single advertising companies for 22 consecutive years. Dentsu's operations are mainly distributed in the United States, Europe, Japan, and other regions. The entire group has over 100 subsidiaries and joint ventures, 65,000 employees, and serves more than 30,000 clients.

KOKUYO, founded in 1905, is a century-old, leading comprehensive office furniture supplier in Japan. Renowned for continuous product innovation and outstanding research and development capabilities, KOKUYO consistently upholds the concept of environmental protection in its products, adheres to "people+design," provides users with healthier and more efficient products, and delivers greater value to a sustainable society. KOKUYO continuously conducts in-depth research on products and work styles, leading the development trend of new office concepts. Co-creating with customers through empathy, KOKUYO creates healthier, more comfortable, and unique office environments for global enterprises.